Renaissance Acquisition Holdings, LLC, a RoundTable Healthcare Partners portfolio company, and GlaxoSmithKline (GSK.L,GSK) announced that they have entered into an agreement giving Renaissance the rights in the USA to manufacture, market and sell six dermatology and three anti-viral products from GSK.
The company said that the products from GSK and Stiefel, a GSK company, which will be marketed through Renaissance's branded division Prestium Pharma, include, Evoclin Foam, 1%, Extina Foam, 2%, Luxiq Foam, 0.12%, Olux Foam, 0.05%, Olux-E Foam, 0.05%, Vusion, Zovirax Capsules, Zovirax Tablets and Zovirax Suspension.
Pierre Fréchette, President and CEO of Renaissance, stated, "This transaction represents a significant milestone for Renaissance, and is in-line with our strategy of acquiring niche products that we can both manufacture within our internal network and market through our strong commercial group. The RoundTable team was instrumental in helping to source, diligence and complete such an important acquisition."
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.